Radioactive Seed Localization Radiation Safety

Radioactive seed localization (RSL) implants a tiny iodine-125 sealed source into a non-palpable breast lesion so a surgeon can find and remove it with a handheld gamma probe. It is low-dose, well-tolerated, and lets the marker be placed days ahead of surgery instead of the morning of the operation. But an implanted seed is licensed radioactive material, and that changes everything about how the program must be run: license, authorized users, written directives, seed accountability from receipt through pathology, and an airtight lost-seed procedure.

Introduction

For decades, the standard way to mark a non-palpable breast lesion for excision was wire localization: on the morning of surgery, a radiologist threaded a hooked wire into the lesion under imaging guidance, and the patient walked to the operating room with the wire protruding from the breast. It works, but it is logistically fragile — the wire must be placed the same day, it can migrate or transect, and it ties the radiology and surgery schedules together tightly.

Radioactive seed localization replaced that workflow at many centers. A radiologist places a small titanium-encapsulated iodine-125 seed into the lesion under ultrasound or mammographic guidance, up to several days before surgery. In the operating room, the surgeon sweeps a handheld gamma probe over the breast, follows the count rate to the seed, and excises the seed within the target tissue. Specimen radiography confirms the seed and lesion are out, and the pathology laboratory recovers the seed from the specimen.¹ The clinical advantages — decoupled scheduling, more accurate targeting, better cosmetic and margin outcomes — are why RSL became popular.²

The catch is regulatory and operational. A seed is byproduct material, so the moment a facility adopts RSL it takes on a radioactive material program that spans four departments — radiology, surgery, nuclear medicine, and pathology — and must satisfy the U.S. Nuclear Regulatory Commission or its Agreement State.³ This article covers the physics that makes RSL safe, the NRC framework that governs it, and the accountability and lost-seed controls that keep a program defensible. DRPS builds these programs as part of its radioactive material license support and radiation safety officer services across Florida, Maryland, Virginia, Washington DC, California, and Nevada.

Topic Explanation

What is radioactive seed localization?

RSL is the use of a low-activity sealed radioactive source, placed inside a lesion before surgery, as a homing beacon for intraoperative gamma-probe–guided excision. The seed is the same physical form factor as a low-dose-rate brachytherapy seed — a titanium capsule a few millimeters long — but it is used to localize, not to treat. The activity is far lower than a therapeutic implant, and the seed is removed with the specimen rather than left in place.

The workflow has four hand-offs, each with a radiation-safety dimension:

Receipt and assay. The seed arrives as licensed material, is logged into inventory, and its activity is verified.
Placement. A credentialed radiologist implants the seed into the lesion under imaging guidance, typically with an 18-gauge needle.¹
Excision. The surgeon uses a gamma probe to find and remove the seed within the target tissue; specimen radiography confirms retrieval.
Pathology recovery. The pathology laboratory locates and removes the seed from the fixed specimen, and the seed is returned to secured storage or decay/disposal.⁴

The same principle extends to marking axillary lymph nodes for targeted removal after neoadjuvant therapy, which is why the current NRC guidance explicitly covers "lesions and lymph nodes."³ For the related radiotracer-based technique used to map sentinel nodes, see our guide to lymphoscintigraphy and sentinel node mapping.

Why the physics makes it low-risk

Two properties of iodine-125 make RSL a genuinely low-dose procedure. First, the activity is small — measured seed activities in a large clinical series ranged from about 1.85 to 5.55 MBq (roughly 0.05 to 0.15 mCi) per seed.¹ Second, iodine-125 emits low-energy photons — characteristic X-rays and gamma rays in the roughly 27–35 keV range — which are strongly attenuated by a few centimeters of tissue and by very thin lead. The combination means the external radiation field around a seeded patient is minimal, and the dose to the surrounding breast tissue is small: published work estimated a maximum dose to residual breast tissue on the order of 2 cGy, comparable to a two-view mammogram, with badge monitoring showing no measurable increase in physician or technologist exposure.¹

Key Technical Principles

Iodine-125: decay and why timing is flexible

Iodine-125 decays by electron capture with a half-life of 59.4 days. The activity remaining after an implant interval $t$ is:

A (t) = A_{0} e^{- λ t}, λ = \frac{ln 2}{T _{1/2}} = \frac{0.693}{59.4 d}

For a seed implanted 5 days before surgery:

\frac{A ( 5 )}{A _{0}} = e^{- (\frac{0.693}{59.4}) \times 5} = e^{- 0.0583} \approx 0.943

About 94% of the initial activity is still present at surgery. This is the physical reason RSL can be scheduled days ahead: unlike a short-lived tracer, the seed's signal barely changes over the placement-to-surgery window. It is also why decay-in-storage is a slow disposal pathway for recovered seeds — a topic the radiation safety program must plan for. For the general framework, see decay-in-storage of radioactive waste.

Low-energy photons are trivially shielded

The 27–35 keV photons of iodine-125 are attenuated far more readily than the higher-energy emissions of typical nuclear-medicine isotopes. The half-value layer in lead at these energies is only about 0.025 mm. Barrier transmission follows:

B = (\frac{1}{2})^{x / HVL}

For an illustrative 0.5 mm lead sheet (about 20 HVLs):

B = (\frac{1}{2})^{0.5/0.025} = 2^{- 20} \approx 1 \times 1 0^{- 6}

Even a thin lead-lined container reduces the already-small external field by six orders of magnitude, and the leaded storage "pig" that ships the seeds provides ample shielding. Practically, this means structural shielding is a non-issue for RSL — the radiation-safety effort goes entirely into accountability, contamination-free handling of a sealed source, and preventing a lost or retained seed, not into barriers. Time, distance, and simple source control dominate; see time, distance, and shielding for external dose.

Comparing localization methods

Method	Radioactive material?	Regulatory oversight	Placement window before surgery	Notes
Wire localization	No	Standard imaging/surgery	Same day	Logistically rigid; wire can migrate
Radioactive seed (I-125)	Yes (byproduct material)	NRC / Agreement State, 10 CFR 35.1000	Up to ~5 days	Decoupled scheduling; requires RAM program
Magnetic seed (e.g., iron-oxide)	No	Device regulation (FDA)	Weeks	MRI-limited susceptibility artifact
Radar / RFID reflector	No	Device regulation (FDA)	Weeks	No radiation program; device cost

Non-radioactive alternatives eliminate the licensing burden, which is a legitimate reason some programs choose them. RSL remains widely used and well validated, with decades of safety data; the right choice depends on device availability, MRI needs, workflow, and whether a facility wants to maintain a radioactive material program.³

Clinical Impact

The clinical case for RSL is strong, but the operational risk is concentrated in a single failure mode: an unaccounted-for seed. Every published safety framework centers on seed accountability and the ability to find a seed that has gone astray — inside the specimen, in the operating room, in the drapes or waste, or, worst case, retained in the patient.

Real-world programs show this can be managed to a very high standard when the workflow is disciplined. A first-year evaluation of a multidisciplinary I-125 seed protocol retrieved 146 seeds from 130 specimens with no seeds lost; the incidents that did occur were mostly minor documentation errors or seeds hidden within tissue slices, and consultation with nuclear medicine resolved the difficult retrievals.⁴ A pathology-laboratory implementation study similarly reported that robust protocols for labeling, tracking, retrieval, and disposal produced no significant radiation exposure to pathologists and no lost seeds.⁵ The lesson is consistent: the technology is safe, and the outcomes depend on process discipline across departments, especially the pathology hand-off where seeds are most often "hidden" in tissue.

Practical Optimization Tips

Build accountability that spans all four departments

The single most important control is a seed-tracking log that follows each seed from receipt → placement → excision → pathology → storage/disposal, with a named responsible person at each hand-off. Reconcile the count at the end of every case. Most RSL incidents are documentation or hand-off failures, not radiation events.⁴

Standardize the intraoperative and specimen survey

The surgeon confirms seed removal with the gamma probe; specimen radiography confirms the seed and lesion are in the specimen before the patient's wound is closed. If the probe or specimen radiograph does not confirm the seed, the case stops and a search begins — this is the moment that prevents a retained seed.

Write the lost-seed procedure before you need it

The program must have a written lost-seed procedure that names who surveys what (OR floor, drapes, suction, waste, specimen, pathology grossing station), with which instrument, and how the search and reconciliation are documented. Rehearse it. A lost seed found calmly in the drapes is a non-event; a lost seed discovered days later in pathology is a crisis.

Match instrumentation to the isotope and keep it in QC

The gamma probe and survey meter must respond to iodine-125's low-energy photons and be included in the instrument QC and calibration program. A probe optimized only for higher-energy isotopes may underperform. See choosing the right radiation survey meter and survey meter calibration.

Common pitfalls to avoid

Treating RSL as "just imaging." It is a use of licensed radioactive material with license, training, and recordkeeping obligations.
A weak pathology hand-off. The pathology grossing station is where seeds are most often lost; it needs its own procedure, survey step, and training.⁵
No named accountability owner per case. Diffuse responsibility is how seeds go missing.
Skipping instrument QC. A probe or meter that is not verified for iodine-125 undermines both the procedure and the lost-seed search.
Assuming a lost seed is minor. Depending on circumstances, it can be a reportable medical event.

Regulatory Considerations

Because an iodine-125 seed is byproduct material, radioactive seed localization is licensed and inspected by the NRC or the relevant Agreement State under 10 CFR Part 35, not by the FDA or the state X-ray program. RSL is authorized as an "other medical use" under 10 CFR 35.1000, and the NRC has issued dedicated licensing guidance to standardize how facilities qualify.³⁶

Key frameworks to reference:

10 CFR 35.1000 (Other Medical Uses) — the pathway under which RSL is authorized, supported by NRC licensing guidance.⁶
NRC licensing guidance for low-activity localization seeds (2016) — the current guidance, titled "Low Activity Radioactive Seeds Used for Localization of Non-Palpable Lesions and Lymph Nodes," which replaced the more burdensome 2006 brachytherapy-based guidance and clarified authorized-user training and experience, written directives, surveys, instrumentation, and medical event criteria appropriate to the low-activity procedure.³
10 CFR Part 20 — Standards for Protection Against Radiation, including occupational and public dose limits and the general radiation-protection program requirements.⁷
10 CFR 20.1801–20.1802 — security and control of licensed material, which underpin seed accountability from receipt through disposal.⁷
10 CFR 35.3045 — the medical event reporting framework; a seed placed in the wrong site, left in the patient, or otherwise mismanaged can meet reportable-event criteria depending on the circumstances. See our guide to medical event reporting under 35.3045.

Agreement States administer their own equivalent programs. Of the states DRPS serves, Florida, Maryland, Virginia, California, Nevada, Pennsylvania, New York, and New Jersey are NRC Agreement States that license and inspect medical use of radioactive material under their own radiation-control rules, while Washington, DC and Delaware are regulated directly by the NRC. A facility must obtain a license amendment authorizing RSL, name authorized users with the required training, and implement written procedures before the first seed is ordered. This work connects to radioactive material license amendments, authorized user training and experience, and securing licensed material under 20.1801–20.1802.

Frequently Asked Questions (FAQs)

What is radioactive seed localization?

Radioactive seed localization (RSL) is a technique in which a small titanium-encapsulated radioactive seed — most often iodine-125 — is implanted into a non-palpable breast lesion or lymph node before surgery. During the operation, the surgeon uses a handheld gamma probe to locate the seed and remove the surrounding tissue. RSL is an alternative to wire localization and lets the marker be placed up to several days before surgery instead of the morning of surgery.

Is radioactive seed localization safe for the patient?

Yes. The seeds are very low activity, and the iodine-125 photons are low energy and are heavily attenuated by tissue, so the radiation dose is small — published work estimates a maximum dose to residual breast tissue on the order of a two-view mammogram. The external dose to staff and family is negligible, and personnel monitoring in published programs has shown no measurable increase in occupational exposure.

How is radioactive seed localization regulated?

Because a radioactive seed is byproduct material, RSL is regulated by the U.S. Nuclear Regulatory Commission or an Agreement State under 10 CFR Part 35, specifically 35.1000 for other medical uses. The NRC issued dedicated licensing guidance for low-activity localization seeds in 2016. A facility needs a radioactive material license amendment, authorized users with appropriate training, written directives, seed accountability, surveys, and a medical event procedure.

What isotope is used and how long does the seed stay in?

Iodine-125 is the most common isotope; palladium-103 has also been used. Iodine-125 has a 59.4-day half-life, so the seed's activity is essentially unchanged over the days between implantation and surgery. Seeds are typically implanted up to about five days before surgery and are removed with the surgical specimen, then recovered by the pathology laboratory.

What happens if a seed is lost?

A lost or unaccounted-for seed is a serious event that the program's procedures must address explicitly. The facility surveys the operating room, specimen, drapes, waste, and pathology materials with a survey meter or gamma probe, documents the search, and reconciles seed accountability records. Depending on the circumstances, a lost seed or a seed left in the patient can meet the criteria for a reportable medical event under NRC rules.

Who needs to be involved in a radioactive seed localization program?

RSL is inherently multidisciplinary. Radiology places the seed, surgery excises it, nuclear medicine or the radiation safety program manages the material and instrumentation, and pathology recovers the seed from the specimen. A qualified medical physicist and the radiation safety officer establish seed accountability, surveys, instrument QC, training, and written procedures across all four departments.

Does radioactive seed localization require written directives and surveys?

The 2016 NRC licensing guidance clarified requirements for RSL, including authorized-user training and experience, written directives, instrumentation, surveys, and medical event criteria appropriate to the low-activity procedure. Facilities should follow the current guidance and their license conditions, which a medical physicist and radiation safety officer translate into department-level standard operating procedures.

How does RSL compare to magnetic seed and radar reflector localization?

Non-radioactive alternatives — magnetic seeds and radar or RFID reflectors — avoid radioactive material and its licensing burden, which is a real advantage for some programs. RSL remains widely used, is well validated, and has decades of safety data. The right choice depends on the facility's device availability, MRI compatibility needs, surgical workflow, and willingness to maintain a radioactive material program.

Key Takeaways

RSL uses a low-activity I-125 sealed source implanted before surgery and retrieved with a gamma probe — a well-validated alternative to wire localization that decouples radiology and surgery scheduling.²
The physics makes it low-dose: small activity plus low-energy 27–35 keV photons mean a maximum residual-tissue dose on the order of a two-view mammogram and negligible staff dose.¹
Iodine-125's 59.4-day half-life keeps the seed's signal essentially constant over a multi-day placement window (about 94% remaining at 5 days).
It is licensed radioactive material under 10 CFR 35.1000, requiring an NRC or Agreement State license amendment, authorized users, written directives, and surveys.³⁶
Seed accountability across four departments is the core control, and the pathology hand-off is where seeds are most often lost.⁴⁵
A written lost-seed procedure is mandatory, and a mismanaged or retained seed can be a reportable medical event.⁷

Conclusion

Radioactive seed localization is a case study in how a physically low-risk procedure can carry meaningful program risk. The radiation itself is almost trivial — a sub-millicurie, low-energy sealed source is shielded by a fraction of a millimeter of lead and delivers a mammogram-scale dose. What demands rigor is that the seed is licensed material moving through four departments, and the whole safety case rests on never losing track of it. Facilities that treat RSL as a radioactive material program — with real accountability, a rehearsed lost-seed procedure, isotope-appropriate instrumentation, and department-level SOPs — get the clinical benefit safely and stay defensible at inspection. Facilities that treat it as "just imaging" are one hidden seed away from a reportable event.

How DRPS Can Help

Diagnostic Radiation Physics Services helps breast-imaging and surgical programs stand up and maintain radioactive seed localization safely. This includes the radioactive material license amendment, authorized-user training documentation, written directives and department SOPs for radiology, surgery, nuclear medicine, and pathology, seed accountability systems, gamma-probe and survey-meter QC, the lost-seed procedure, and radiation safety officer and medical physics consulting support aligned with NRC and Agreement State requirements.

DRPS supports facilities across our service locations, including Florida, Maryland, Virginia, Washington DC, California, Nevada, New York, Pennsylvania, New Jersey, and Delaware.

A good RSL program makes the safe path the easy path — so the seed is always accounted for, every case, every department.

Related Resources

References

Pavlicek W, Walton HA, Karstaedt PJ, Gray RJ. Radiation safety with use of I-125 seeds for localization of nonpalpable breast lesions. Acad Radiol. 2006;13(7):909-915. doi:10.1016/j.acra.2006.03.017. doi.org
Jakub JW, Gray RJ, Degnim AC, Boughey JC, Gardner M, Cox CE. Current status of radioactive seed for localization of non palpable breast lesions. Am J Surg. 2009;199(4):522-528. doi:10.1016/j.amjsurg.2009.05.019. doi.org
Sheetz M, Steiner C. Compliance with the U.S. Nuclear Regulatory Commission revised licensing guidance for radioactive seed localization. Health Phys. 2018;115(3):402-408. doi:10.1097/HP.0000000000000889. doi.org
Rodríguez-Villena A, Schmülling UCV, Zapata IV, et al. Implementation of a multidisciplinary protocol for the safe handling of iodine-125 radioactive seeds in the pathology laboratory. Int J Breast Cancer. 2026;2026:3962099. doi:10.1155/ijbc/3962099. doi.org
Dessauvagie BF, Frost FA, Sterrett GF, et al. Handling of radioactive seed localisation breast specimens in the histopathology laboratory: the Western Australian experience. Pathology. 2015;47(1):21-26. doi:10.1097/PAT.0000000000000197. doi.org
U.S. Nuclear Regulatory Commission. Iodine-125 and Palladium-103 Low Dose Rate Brachytherapy Seeds Used for Localization of Non-Palpable Lesions — Emerging and Licensed Medical Technologies. nrc.gov
U.S. Nuclear Regulatory Commission. 10 CFR Part 20: Standards for Protection Against Radiation, and 10 CFR Part 35: Medical Use of Byproduct Material. ecfr.gov